Modern oncological and operative outcomes in oesophageal cancer: the St. James's hospital experience.
Anastomotic leak
Oesophageal adenocarcinoma
Oesophageal cancer incidence
Oesophageal squamous cell carcinoma
Oesophageal surgery complications
Oncological outcomes
Journal
Irish journal of medical science
ISSN: 1863-4362
Titre abrégé: Ir J Med Sci
Pays: Ireland
ID NLM: 7806864
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
06
06
2020
accepted:
17
07
2020
pubmed:
23
7
2020
medline:
9
3
2021
entrez:
23
7
2020
Statut:
ppublish
Résumé
Oesophageal cancer has a reputation for poor survival, and a relatively high risk of major postoperative morbidity and mortality. Encouragingly, a recent international cancer registry study reports a doubling of survival outcomes in Ireland over the last 20 years. This study focused on both oncologic and operative outcomes in patients treated with curative intent requiring surgery at a high-volume center. All patients undergoing surgery or multimodal therapy with curative intent from 2009 to 2018 were studied. All data was recorded prospectively and maintained internally. The period 2009-2013 was compared with 2014-2018 to monitor any change in trends. Four hundred and seventy-five patients (adenocarcinoma 77%, mean age 65; 76% male; 64% neoadjuvant therapy) underwent open surgical resection, 54% via en bloc 2-stage, 19.8% en bloc 3-stage, and 26.5% by a transhiatal approach. New onset atrial fibrillation was the commonest index complication, in 108 (22.7%), 80 (18%) developed suspected pneumonia/respiratory tract infection, 20 (4.2%) an anastomotic leak, and 25 (5.2%) a chyle leak. The 90-day mortality rate was 1.2% and 0.8% at 30 days. The median survival was 77.17 months, with a 5-year survival of 56%. Consistent with registry data on population survival for oesophageal cancer, this study highlights markedly improved survival outcomes in patients treated curatively, reflecting international trends, as well as low mortality rates; however, cardiorespiratory complications remain significant.
Sections du résumé
BACKGROUND
BACKGROUND
Oesophageal cancer has a reputation for poor survival, and a relatively high risk of major postoperative morbidity and mortality. Encouragingly, a recent international cancer registry study reports a doubling of survival outcomes in Ireland over the last 20 years. This study focused on both oncologic and operative outcomes in patients treated with curative intent requiring surgery at a high-volume center.
METHODS
METHODS
All patients undergoing surgery or multimodal therapy with curative intent from 2009 to 2018 were studied. All data was recorded prospectively and maintained internally. The period 2009-2013 was compared with 2014-2018 to monitor any change in trends.
RESULTS
RESULTS
Four hundred and seventy-five patients (adenocarcinoma 77%, mean age 65; 76% male; 64% neoadjuvant therapy) underwent open surgical resection, 54% via en bloc 2-stage, 19.8% en bloc 3-stage, and 26.5% by a transhiatal approach. New onset atrial fibrillation was the commonest index complication, in 108 (22.7%), 80 (18%) developed suspected pneumonia/respiratory tract infection, 20 (4.2%) an anastomotic leak, and 25 (5.2%) a chyle leak. The 90-day mortality rate was 1.2% and 0.8% at 30 days. The median survival was 77.17 months, with a 5-year survival of 56%.
CONCLUSION
CONCLUSIONS
Consistent with registry data on population survival for oesophageal cancer, this study highlights markedly improved survival outcomes in patients treated curatively, reflecting international trends, as well as low mortality rates; however, cardiorespiratory complications remain significant.
Identifiants
pubmed: 32696244
doi: 10.1007/s11845-020-02321-4
pii: 10.1007/s11845-020-02321-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
297-305Références
Arnold M, Laversanne M, Brown LM et al (2017) Predicting the Future Burden of Oesophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030. Am J Gastroenterol 112:1247–1255. 2017/06/07. https://doi.org/10.1038/ajg.2017.155
doi: 10.1038/ajg.2017.155
pubmed: 28585555
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBACAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424
doi: 10.3322/caac.21492
O’Sullivan J, Lysaght J, Donohoe CL, Reynolds JV (2018) Obesity and gastrointestinal cancer : the interrelationship of adipose and tumour microenvironments. Nat Rev Gastroenterol Hepatol 15:699–714
doi: 10.1038/s41575-018-0069-7
Van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW et al (2012) Preoperative chemoradiotherapy for oesophageal or junctional cancer. N Engl J Med 366:2074–2084
doi: 10.1056/NEJMoa1112088
Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde C, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20
doi: 10.1056/NEJMoa055531
Al-Batran SE, Homann N, Pauligk C, Goetze TO et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin and docetaxel versus fluorouracil or capecitabline plus cisplatin and epirubicin for locally advanced resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomied, phase 2/3 trial. Lancet etc
Low DE, Kuppusamy MJ, Alderson D, Cecconello I et al (2019) Benchmarking complicatons associated with esophagectomy. Ann Surg 269:291–298
doi: 10.1097/SLA.0000000000002611
Lagergren K, Smyth E, Cunningham D et al (2017) Oesophageal cancer. Lancet 390:2383–2396
doi: 10.1016/S0140-6736(17)31462-9
Reynolds JV, Donohoe CL, McGillycuddy E, Ravi N, O’Toole D, O’Byrne K, Hollywood D (2012) Evolving progress in oncologic and operative outcomes for oesophageal and junctional cancer: lessons from the experience of a high-volume center. J Thorac Cardiovasc Surg 143:1130–1137
doi: 10.1016/j.jtcvs.2011.12.003
Biere SS, van Berge Henegouwen MI, Maas KW et al (2012) Minimally invasive versus open oesopgectomy for patients with oesophageal cancer; a multi-centre , open label, randomised controlled trial. Lancet 379:1887–1892
doi: 10.1016/S0140-6736(12)60516-9
Mariette C, Markar SR, Dabakuyo-Yonli TS, Meunier B, Pezet D, Collet D, D'Journo XB, Brigand C, Perniceni T, Carrère N, Mabrut JY, Msika S, Peschaud F, Prudhomme M, Bonnetain F, Piessen G, Fédération de Recherche en Chirurgie (FRENCH) and French Eso-Gastric Tumors (FREGAT) Working Group (2019) Hybrid minimally invasive esophagectomy for oesophageal cancer. N Engl J Med 380:152–162
doi: 10.1056/NEJMoa1805101
van der Sluis PC, van der Horst S, May AM, Schipper C et al (2019) Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable oesophageal cancer, a randomized controlled trial. (ROBOT trial). Ann Surg 269:621–630
doi: 10.1097/SLA.0000000000003031
Arnold M, Rutherford MJ, Bardot A et al (2019) Progress in cancer survival, mortality, and incidence in seven hgith income countries 1995-2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 0. https://doi.org/10.1016/S1470-2045(19)30456-5
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
doi: 10.1097/01.sla.0000133083.54934.ae
Rice TW, Patil DT, Blackstone EH (2017) 8
doi: 10.21037/acs.2017.03.14
Njei B, Mc Carthy TY, Birk JW (2016) Trends in oesophageal cancer survival in United States adults from 1973 to 2009: a SEER data base analysis. J Gastoenterol Hepatol 31:1141–1146
doi: 10.1111/jgh.13289
Van Putten M, de Cose-Geelen J, Nieuenhuijzen GAP, Siersema PD et al (2018) Long-term survival improvement in oesophageal cancer in the Netherlands. Eur J Cancer 94:138–147
doi: 10.1016/j.ejca.2018.02.025
Donohoe CL, O’Farrell NJ, Grant T, King S et al (2013) Classification of pathologic response to neoadjuvant therapy in oesophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard. Ann Surg 258:784–792
doi: 10.1097/SLA.0b013e3182a66588
Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ (1996) A comparison of multimodal therapy and surgery for oesophageal adenocarcinoma. N Engl J Med 335:462–467
doi: 10.1056/NEJM199608153350702
Chang KH, McAnena OJ, Smith MH, Salman RR et al (2010) Surgery for oesophageal cancer at Galway University Hospital 1993-2008. Ir J Med Sci 72:521–527
doi: 10.1007/s11845-010-0573-4
Earlam R, Cunha-Melo JR (1980) Oesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg 67:381–390
doi: 10.1002/bjs.1800670602
Muller JM, Erasmi H, Stelzner M et al (1990) Surgical therapy of oesophageal carcinoma. Br J Surg 77:845–847
doi: 10.1002/bjs.1800770804
Jamieson GG, Mathew G, Ludemann R, Wayman J, Myers JC, Devitt PG (2004) Postoperative mortality following oesophagectomy and problems in reporting its rate. Br J Surg 91:943–947
doi: 10.1002/bjs.4596
Low DE, Kunz D, Schembre D, Otero H et al (2007) Esophagectomy – it’s not just about mortality anymore: standardized perioperative clinical pathways improve outcomes in patient with oesophageal cancer. J Gastrointest Surg 11:1395–1402
doi: 10.1007/s11605-007-0265-1
Van der Werf LR, Busweiler LAD, can Sandick JW, van Berge H, Wijnhoven BP, the DUCA group (2019) Reporting national outcomes after esophagectomy and gastrecomy according to the the Oesophageal Complications Consensus Group (ECCG). Ann Surg
Low DE, Allum W, De Manzoni G, Ferri L et al (2019) Guidelines for perioperative care in esophagectomy: enhanced recovery after surgery (ERAS) society recommendations. World J Surg 43:299–330
doi: 10.1007/s00268-018-4786-4
Guinan EM, Dowds J, Donohoe CL, Reynolds JV, Hussey J (2017) The physiotherapist and the oesophageal cancer patient: from pre-habilitation to rehabilitation. Dis Oesophagus 30:1–12
doi: 10.1093/dote/dox018
Van Workum F, Stensrta MH, Berkelmans GH et al (2019) Learning curve and associated morbidity of minimaly invasive esophagectomy: a tretoerspective multicenter study. Ann Surg 269:88–94
doi: 10.1097/SLA.0000000000002469
Carroll PA, Jacob N, Yeung JC, Darling GE (2020) Using benchmarking standards to evaluate transition to minimally invasive esophagectomy. Ann Thorac Surg 109:383–388
doi: 10.1016/j.athoracsur.2019.08.019
Govindan S, Hyzy RC (2016) The 2016 guidelines for hospital-acquired and ventilator-associated pneumonia. A selection correction? Am J Respir Crit Care Med 194:658–660
doi: 10.1164/rccm.201607-1447ED
Mc Cormack O, Zaborowski A, King S, Healy L, Daly C, OʼFarrell N, Donohoe CL, Ravi N, Reynolds JV (2014) New onset atrial fibrillation post-surgery for oesophageal and junctional cancer: incidence, management and implications on short and long-term outcomes. Ann Surg 260:772–778
doi: 10.1097/SLA.0000000000000960